𝔖 Bobbio Scriptorium
✦   LIBER   ✦

441 POSTER Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models

✍ Scribed by H.P. McDowell; D. Meco; A. Riccardi; B. Tanno; A. Berardi; G. Raschellà; R. Riccardi; C. Dominici

Book ID
118624069
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
61 KB
Volume
4
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate potentiates topotecan
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models
✍ Heather P. McDowell; Daniela Meco; Anna Riccardi; Barbara Tanno; Anna C. Berardi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 331 KB

## Abstract High levels of PDGFR expression in primary rhabdomyosarcoma (RMS) have been associated with disease progression. To date however, there are no reports on the activity of imatinib mesylate, a selective PDGFR inhibitor, in RMS preclinical models. A panel of 5 RMS cell lines was used to in